{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:13:16Z","timestamp":1773270796235,"version":"3.50.1"},"reference-count":71,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie-Herz und Kreislaufforschung.","doi-asserted-by":"publisher","award":["DGK02\/2022"],"award-info":[{"award-number":["DGK02\/2022"]}],"id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Purpose<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio\u2010oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI\u2010associated cardiovascular complications remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Approach<\/jats:title>\n                    <jats:p>We analysed 539 cancer patients under ICI therapy from the Essen Cardio\u2010oncology Registry (EcoR). Patients were stratified by enrolment period (2018\u20132020 vs. 2021\u20132023), with cancer therapy\u2010related cardiovascular toxicity (CTR\u2010CVT) and overall survival evaluated during follow\u2010up. This included myocarditis, vascular toxicity, cancer therapy\u2010related cardiac dysfunction (CTRCD), arrhythmia and arterial hypertension. CTRCD ranges from elevated cardiac biomarkers, declined cardiac function to decompensated heart failure. Arrhythmia included sinus bradycardia or tachycardia atrial fibrillation and QTc prolongation. Median follow\u2010up time was 486\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>\n                      Patients enrolled between 2021 and 2023 showed higher incidence of myocarditis (odds ratio [OR]: 2.64; 95% confidence interval [CI]: 1.10\u20136.36;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03), sinus bradycardia (OR: 5.50; 95% CI: 1.22\u201324.80;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03) and atrial fibrillation (OR: 2.23; 95% CI: 1.16\u20134.28;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02). This was associated with higher rates of combined ICI therapy and improved overall survival. Conversely, vascular toxicity was significantly reduced (OR 0.05; 95% CI: 0.01\u20130.40;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004), paralleling greater statin utilization (14.5% vs. 23.6%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Implications<\/jats:title>\n                    <jats:p>The observed association between statin use and reduced vascular toxicity suggests a potential protective strategy in this high\u2010risk population, warranting further investigation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bph.70408","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:04:22Z","timestamp":1773216262000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio\u2010oncology Registry"],"prefix":"10.1111","author":[{"given":"Elias","family":"Haj\u2010Yehia","sequence":"first","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Lampe","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Vlachopoulou","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Totzeck","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca I.","family":"Mincu","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen University Hospital Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.05.025"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70232"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70230"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70233"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70234"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70229"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-025-01165-8"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.049"},{"issue":"7937","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for alpha\u2010myosin drive immunotherapy\u2010related myocarditis","volume":"611","author":"Axelrod M. L.","year":"2022","journal-title":"Nature"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.02.004"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1726"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.072"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01090-w"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01070-0"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/11594010-000000000-00000"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.62347\/ZKIG9938"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.882167"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17441"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa884"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01046-0"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.08.001"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677984"},{"issue":"19","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous\u2010cell carcinoma of the head and neck","volume":"375","author":"Ferris R. L.","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.962596"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01068-8"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw022"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-025-00697-x"},{"issue":"3","key":"e_1_2_13_35_1","first-page":"727","article-title":"PD\u20101\/PD\u2010L1 pathway: Current researches in cancer","volume":"10","author":"Han Y.","year":"2020","journal-title":"American Journal of Cancer Research"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad111"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa199"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00687.2024"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00326-6"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02583-2"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-017-0660-z"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051145"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-11095-w"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.04.037"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab430"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002478"},{"issue":"12","key":"e_1_2_13_51_1","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T\u2010lymphocyte antigen\u20104 (CTLA\u20104): A novel strategy for the treatment of melanoma and other malignancies","volume":"110","author":"O'Day S. J.","year":"2007","journal-title":"Cancer"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01077-7"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00097-8"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf136"},{"issue":"19","key":"e_1_2_13_58_1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD\u2010L1\u2010positive non\u2010small\u2010cell lung cancer","volume":"375","author":"Reck M.","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00497-0"},{"issue":"7","key":"e_1_2_13_61_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1524-6175.2004.02866.x","article-title":"Angiotensin\u2010converting enzyme inhibitors side effects\u2014Physiologic and non\u2010physiologic considerations","volume":"6","author":"Sica D. A.","year":"2004","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01080-y"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36614-w"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115339"},{"issue":"4","key":"e_1_2_13_66_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/cvr\/cvr148","article-title":"IL\u20106\u2010mediated Th17 differentiation through RORgammat is essential for the initiation of experimental autoimmune myocarditis","volume":"91","author":"Yamashita T.","year":"2011","journal-title":"Cardiovascular Research"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.01.016"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01414-4"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3113"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.11.012"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo1981"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550400"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.70408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bph.70408","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.70408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:04:24Z","timestamp":1773216264000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.70408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":71,"alternative-id":["10.1111\/bph.70408"],"URL":"https:\/\/doi.org\/10.1111\/bph.70408","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bph.70408"}}